|Articles|June 1, 2002
Phaco advance minimizes risk of endothelial cell loss
Rockville Centre, NY-Sonolase, a new mode of phacoemulsification power produced by the WhiteStar software for the Sovereign system (Advanced Medical Optics Inc. [AMO], the new entity formed in the recent Allergan spin-off), reduces the amount of energy expended in the eye and minimizes corneal endothelial cell loss.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
























